Search research articles
Contact Us
Filters
Showing results (41-50 of 84) with videos related to
Page
of 9
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 29, 2021
A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions
James W Shaw, Bryan Bennett, Andrew Trigg, et al.
Orphanet Journal of Rare Diseases
|
March 25, 2023
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF<sup>©</sup>) and determination of a threshold score for moderate symptoms
Alan L Shields, Fiona Taylor, Roger E Lamoureux, et al.
Orphanet Journal of Rare Diseases
|
October 10, 2021
Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF<sup>©</sup>
Fiona Taylor, Cem Akin, Roger E Lamoureux, et al.
Orphanet Journal of Rare Diseases
|
October 19, 2021
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study
Brad Padilla, Alan L Shields, Fiona Taylor, et al.
The Lancet. Oncology
|
June 11, 2016
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
David Cella, Viktor Grünwald, Paul Nathan, et al.
Hemasphere
|
March 2, 2023
Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial
Katja Weisel, Meletios A Dimopoulos, Jesús San-Miguel, et al.
Leukemia Research
|
May 18, 2021
Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF)
Fiona Taylor, Xiaoran Li, Christine Yip, et al.
The Patient
|
March 30, 2016
Development of a Symptom-Based Patient-Reported Outcome Instrument for Functional Dyspepsia: A Preliminary Conceptual Model and an Evaluation of the Adequacy of Existing Instruments
Fiona Taylor, David S Reasner, Robyn T Carson, et al.
The American Journal of Gastroenterology
|
September 20, 2017
Development of a Symptom-Focused Patient-Reported Outcome Measure for Functional Dyspepsia: The Functional Dyspepsia Symptom Diary (FDSD)
Fiona Taylor, Sophie Higgins, Robyn T Carson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2011
Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience
Uday B Patel, Fiona Taylor, Lennart Blomqvist, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 84) with videos related to
Sort By:
Page
of 9
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 29, 2021
A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions
James W Shaw, Bryan Bennett, Andrew Trigg, et al.
Orphanet Journal of Rare Diseases
|
March 25, 2023
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF<sup>©</sup>) and determination of a threshold score for moderate symptoms
Alan L Shields, Fiona Taylor, Roger E Lamoureux, et al.
Orphanet Journal of Rare Diseases
|
October 10, 2021
Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF<sup>©</sup>
Fiona Taylor, Cem Akin, Roger E Lamoureux, et al.
Orphanet Journal of Rare Diseases
|
October 19, 2021
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study
Brad Padilla, Alan L Shields, Fiona Taylor, et al.
The Lancet. Oncology
|
June 11, 2016
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
David Cella, Viktor Grünwald, Paul Nathan, et al.
Hemasphere
|
March 2, 2023
Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial
Katja Weisel, Meletios A Dimopoulos, Jesús San-Miguel, et al.
Leukemia Research
|
May 18, 2021
Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF)
Fiona Taylor, Xiaoran Li, Christine Yip, et al.
The Patient
|
March 30, 2016
Development of a Symptom-Based Patient-Reported Outcome Instrument for Functional Dyspepsia: A Preliminary Conceptual Model and an Evaluation of the Adequacy of Existing Instruments
Fiona Taylor, David S Reasner, Robyn T Carson, et al.
The American Journal of Gastroenterology
|
September 20, 2017
Development of a Symptom-Focused Patient-Reported Outcome Measure for Functional Dyspepsia: The Functional Dyspepsia Symptom Diary (FDSD)
Fiona Taylor, Sophie Higgins, Robyn T Carson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2011
Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience
Uday B Patel, Fiona Taylor, Lennart Blomqvist, et al.
Page
of 9